C Rauh1, F Schuetz2, B Rack3, E Stickeler4, M Klar4, M Orlowska-Volk5, M Windfuhr-Blum6, J Heil2, J Rom2, C Sohn2, U Andergassen3, J Jueckstock3, T Fehm7, C R Loehberg1, A Hein1, R Schulz-Wendtland8, A Hartmann9, M W Beckmann1, W Janni10, P A Fasching11, L Häberle12. 1. University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen. 2. Breast Unit, Department of Gynecology and Obstetrics, Heidelberg University Hospital. 3. Department of Gynecology and Obstetrics, Campus Innenstadt University Hospital, Ludwig Maximilian University, Munich. 4. Department of Obstetrics and Gynecology, Freiburg University Medical Center, Freiburg. 5. Institute of Pathology, Freiburg University Medical Center, Freiburg. 6. Department of Radiology, Freiburg University Medical Center, Freiburg. 7. Department of Gynecology and Obstetrics, Duesseldorf University Hospital, Düsseldorf. 8. Institute of Diagnostic Radiology, University Breast Center, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen. 9. Institute of Pathology, University Breast Center, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen. 10. Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm. 11. University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen ; Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine, University of California at Los Angeles, USA. 12. University Breast Center, Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center EMN, Erlangen ; Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen.
Abstract
Introduction: Use of hormone therapy (HT) has declined dramatically in recent years. Some studies have reported that HT use before a diagnosis of breast cancer (BC) may be a prognostic factor in postmenopausal patients. This study aimed to examine the prognostic relevance of HT use before BC diagnosis. Methods: Four BC cohort studies in Germany were pooled, and 4492 postmenopausal patients with HT use data were identified. Patient data and tumor characteristics were compared between users and nonusers, along with overall survival (OS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Cox proportional hazards models were stratified by study center and adjusted for age at diagnosis, tumor stage, grading, nodal status, and hormone receptors. Results: Women with HT use before the diagnosis of BC were more likely to have a lower tumor stage, to be estrogen receptor-negative, and to have a lower grading. With regard to prognosis there were effects seen for OS, DMFS and LRFS, specifically in the subgroup of women with a positive hormone receptor. In these subgroups, BC patients had a better prognosis with previous HT use. Conclusions: HT use before a diagnosis of BC is associated with a more favorable prognosis in women with a positive hormone receptor status. It may be recommended that the prognostic factor HT should be documented and analyzed as a confounder for prognosis in studies of postmenopausal hormone-responsive breast cancers.
Introduction: Use of hormone therapy (HT) has declined dramatically in recent years. Some studies have reported that HT use before a diagnosis of breast cancer (BC) may be a prognostic factor in postmenopausal patients. This study aimed to examine the prognostic relevance of HT use before BC diagnosis. Methods: Four BC cohort studies in Germany were pooled, and 4492 postmenopausal patients with HT use data were identified. Patient data and tumor characteristics were compared between users and nonusers, along with overall survival (OS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Cox proportional hazards models were stratified by study center and adjusted for age at diagnosis, tumor stage, grading, nodal status, and hormone receptors. Results:Women with HT use before the diagnosis of BC were more likely to have a lower tumor stage, to be estrogen receptor-negative, and to have a lower grading. With regard to prognosis there were effects seen for OS, DMFS and LRFS, specifically in the subgroup of women with a positive hormone receptor. In these subgroups, BC patients had a better prognosis with previous HT use. Conclusions: HT use before a diagnosis of BC is associated with a more favorable prognosis in women with a positive hormone receptor status. It may be recommended that the prognostic factor HT should be documented and analyzed as a confounder for prognosis in studies of postmenopausal hormone-responsive breast cancers.
Entities:
Keywords:
breast cancer; hormone receptors; hormone therapy; prognosis
Authors: Matthias W Beckmann; Cosima Brucker; Volker Hanf; Claudia Rauh; Mayada R Bani; Stefanie Knob; Sabrina Petsch; Stefan Schick; Peter A Fasching; Arndt Hartmann; Michael P Lux; Lothar Häberle Journal: Onkologie Date: 2011-06-15
Authors: P A Fasching; A B Ekici; D L Wachter; A Hein; C M Bayer; L Häberle; C R Loehberg; M Schneider; S M Jud; K Heusinger; M Rübner; C Rauh; M R Bani; M P Lux; R Schulz-Wendtland; A Hartmann; M W Beckmann Journal: Geburtshilfe Frauenheilkd Date: 2013-12 Impact factor: 2.915
Authors: P Bonnier; F Bessenay; A J Sasco; B Beedassy; C Lejeune; S Romain; C Charpin; L Piana; P M Martin Journal: Int J Cancer Date: 1998-06-19 Impact factor: 7.396
Authors: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245
Authors: Roger L Milne; Javier Benítez; Heli Nevanlinna; Tuomas Heikkinen; Kristiina Aittomäki; Carl Blomqvist; José Ignacio Arias; M Pilar Zamora; Barbara Burwinkel; Claus R Bartram; Alfons Meindl; Rita K Schmutzler; Angela Cox; Ian Brock; Graeme Elliott; Malcolm W R Reed; Melissa C Southey; Letitia Smith; Amanda B Spurdle; John L Hopper; Fergus J Couch; Janet E Olson; Xianshu Wang; Zachary Fredericksen; Peter Schürmann; Michael Bremer; Peter Hillemanns; Thilo Dörk; Peter Devilee; Christie J van Asperen; Rob A E M Tollenaar; Caroline Seynaeve; Per Hall; Kamila Czene; Jianjun Liu; Yuqing Li; Shahana Ahmed; Alison M Dunning; Melanie Maranian; Paul D P Pharoah; Georgia Chenevix-Trench; Jonathan Beesley; Natalia V Bogdanova; Natalia N Antonenkova; Iosif V Zalutsky; Hoda Anton-Culver; Argyrios Ziogas; Hiltrud Brauch; Christina Justenhoven; Yon-Dschun Ko; Susanne Haas; Peter A Fasching; Reiner Strick; Arif B Ekici; Matthias W Beckmann; Graham G Giles; Gianluca Severi; Laura Baglietto; Dallas R English; Olivia Fletcher; Nichola Johnson; Isabel dos Santos Silva; Julian Peto; Clare Turnbull; Sarah Hines; Anthony Renwick; Nazneen Rahman; Børge G Nordestgaard; Stig E Bojesen; Henrik Flyger; Daehee Kang; Keun-Young Yoo; Dong-Young Noh; Arto Mannermaa; Vesa Kataja; Veli-Matti Kosma; Montserrat García-Closas; Stephen Chanock; Jolanta Lissowska; Louise A Brinton; Jenny Chang-Claude; Shan Wang-Gohrke; Chen-Yang Shen; Hui-Chun Wang; Jyh-Cherng Yu; Sou-Tong Chen; Marina Bermisheva; Tatjana Nikolaeva; Elza Khusnutdinova; Manjeet K Humphreys; Jonathan Morrison; Radka Platte; Douglas F Easton Journal: J Natl Cancer Inst Date: 2009-06-30 Impact factor: 13.506
Authors: C Stahlberg; A T Pedersen; Z J Andersen; N Keiding; Y A Hundrup; E B Obel; S Møller; F Rank; B Ottesen; E Lynge Journal: Br J Cancer Date: 2004-08-16 Impact factor: 7.640
Authors: Lothar Häberle; Alexander Hein; Matthias Rübner; Michael Schneider; Arif B Ekici; Paul Gass; Arndt Hartmann; Rüdiger Schulz-Wendtland; Matthias W Beckmann; Wing-Yee Lo; Werner Schroth; Hiltrud Brauch; Peter A Fasching; Marius Wunderle Journal: Geburtshilfe Frauenheilkd Date: 2017-06-28 Impact factor: 2.915
Authors: Bernard Rosner; Robert J Glynn; A Heather Eliassen; Susan E Hankinson; Rulla M Tamimi; Wendy Y Chen; Michelle D Holmes; Yi Mu; Cheng Peng; Graham A Colditz; Walter C Willett; Shelley S Tworoger Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-08-02 Impact factor: 4.090
Authors: Marco Padilla-Rodriguez; Sara S Parker; Deanna G Adams; Thomas Westerling; Julieann I Puleo; Adam W Watson; Samantha M Hill; Muhammad Noon; Raphael Gaudin; Jesse Aaron; Daoqin Tong; Denise J Roe; Beatrice Knudsen; Ghassan Mouneimne Journal: Nat Commun Date: 2018-07-30 Impact factor: 14.919